{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:18:00Z","timestamp":1790698680495,"version":"4.1.0"},"reference-count":79,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Named after the two-faced Roman god of doorways, Janus kinases (JAKs) represent a class of tyrosine kinases. The JAK signaling pathway is pivotal for the downstream signaling of inflammatory cytokines, including interleukins, interferons, and multiple growth factors. This article provides an overview of the JAK pathway and signaling, its significance in immune-mediated dermatologic diseases and the development of a targeted, localized option of a selective JAK inhibitor, ruxolitinib cream. In the early 1990s, various discovery and clinical development programs were initiated to explore pharmaceutical inhibition of the JAK-STAT pathway. Incyte Corporation launched a strategy to identify molecules suitable for both topical as well as oral delivery. Ruxolitinib was designed as a molecule with low nanomolar potency selective for JAK1 and 2 enzymes, but without significant inhibition of non-JAK kinases, as well as physicochemical properties for both topical and oral administration. An oil-in-water emulsified ruxolitinib cream formulation was developed for topical application and was studied in multiple immune-mediated dermatologic diseases including psoriasis, alopecia areata, atopic dermatitis and vitiligo. Ruxolitinib cream represents a novel, JAK1\/2 selective therapy that can be delivered directly to the skin to treat a number of cytokine-driven, inflammatory dermatoses.<\/jats:p>","DOI":"10.3390\/pharmaceutics13071044","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T10:42:17Z","timestamp":1625740937000},"page":"1044","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream"],"prefix":"10.3390","volume":"13","author":[{"given":"Paul","family":"Smith","sequence":"first","affiliation":[{"name":"Incyte Research Institute, 1801 Augustine Cut-Off, Wilmington, DE 19803, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Yao","sequence":"additional","affiliation":[{"name":"Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, DE 19803, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Shepard","sequence":"additional","affiliation":[{"name":"Incyte Research Institute, 1801 Augustine Cut-Off, Wilmington, DE 19803, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryanne","family":"Covington","sequence":"additional","affiliation":[{"name":"Incyte Research Institute, 1801 Augustine Cut-Off, Wilmington, DE 19803, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Lee","sequence":"additional","affiliation":[{"name":"Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, DE 19803, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Lofland","sequence":"additional","affiliation":[{"name":"Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, DE 19803, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Naim","sequence":"additional","affiliation":[{"name":"Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, DE 19803, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trupti","family":"Sheth","sequence":"additional","affiliation":[{"name":"Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, DE 19803, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavnish","family":"Parikh","sequence":"additional","affiliation":[{"name":"Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, DE 19803, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swamy","family":"Yeleswaram","sequence":"additional","affiliation":[{"name":"Incyte Research Institute, 1801 Augustine Cut-Off, Wilmington, DE 19803, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"a011205","DOI":"10.1101\/cshperspect.a011205","article-title":"The Jak\/STAT pathway","volume":"4","author":"Harrison","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","article-title":"The JAK-STAT pathway at twenty","volume":"36","author":"Stark","year":"2012","journal-title":"Immunity"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.1038\/sj.onc.1203925","article-title":"Janus kinases: Components of multiple signaling pathways","volume":"19","author":"Rane","year":"2000","journal-title":"Oncogene"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.semcdb.2008.08.010","article-title":"Inteferons pen the JAK-STAT pathway","volume":"19","author":"Schindler","year":"2008","journal-title":"Semin. Cell. Dev. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3389\/fimmu.2019.02342","article-title":"Targeting the Janus kinase family in autoimmune skin diseases","volume":"10","author":"Howell","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory disease","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrrheum.2014.127","article-title":"IL-6 biology: Implications for clinical targeting in rheumatic disease","volume":"10","author":"Calabrese","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1172\/JCI200318921","article-title":"C-reactive protein: A critical update","volume":"111","author":"Pepys","year":"2003","journal-title":"J. Clin. Invest."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): Replicate, phase 3, randomised, double-blind, placebo-controlled trials","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: A randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"Holland","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: Impact on human disease and therapeutic intervention","volume":"66","author":"Schwartz","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.immuni.2016.07.022","article-title":"Phosphoproteomic analyses of interleukin 2 signaling reveal integrated JAK kinase-dependent and -independent networks in CD8+ T cells","volume":"45","author":"Ross","year":"2016","journal-title":"Immunity"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.270.5237.797","article-title":"Mutation of Jak3 in a patient with SCID: Essential role of Jak3 in lymphoid development","volume":"270","author":"Russell","year":"1995","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/377065a0","article-title":"Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)","volume":"377","author":"Macchi","year":"1995","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0960-894X(02)00106-3","article-title":"Photochemical preparation of a pyridone containing tetracycle: A Jak protein kinase inhibitor","volume":"12","author":"Thompson","year":"2002","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1126\/science.1087061","article-title":"Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor","volume":"302","author":"Changelian","year":"2003","journal-title":"Science"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2006-01-013540","article-title":"The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera","volume":"108","author":"Lippert","year":"2006","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S340","DOI":"10.3816\/CLM.2009.s.033","article-title":"JAK2 inhibitors: A reality? A hope?","volume":"9","author":"Apostolidou","year":"2009","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"(2010). Deal watch: Dipping into Incyte\u2019s JAK-pot. Nat. Rev. Drug. Discov., 9, 94.","DOI":"10.1038\/nrd3113"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/BOR.0b013e32835fd828","article-title":"Small molecular compounds in development for rheumatoid arthritis","volume":"25","year":"2013","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1517\/13543784.2014.918604","article-title":"Selective JAK inhibitors in development for rheumatoid arthritis","volume":"23","author":"Norman","year":"2014","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1016\/j.bbamem.2006.06.021","article-title":"The skin barrier in healthy and diseased state","volume":"1758","author":"Bouwstra","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/ci200387c","article-title":"Revisiting the general solubility equation: In silico prediction of aqueous solubility incorporating the effect of topographical polar surface area","volume":"52","author":"Ali","year":"2012","journal-title":"J. Chem. Inf. Model"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"173242","DOI":"10.1016\/j.ejphar.2020.173242","article-title":"Small molecule drugs for the treatment of pruritus in patients with atopic dermatitis","volume":"881","author":"Soeberdt","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1021\/acs.jmedchem.6b01868","article-title":"Design and synthesis of enantiomerically pure decahydroquinoxalines as potent and selective \u03ba-opioid receptor agonists with anti-inflammatory activity in vivo","volume":"60","author":"Soeberdt","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.drudis.2009.07.014","article-title":"The impact of aromatic ring count on compound developability\u2014Are too many aromatic rings a liability in drug design?","volume":"14","author":"Ritchie","year":"2009","journal-title":"Drug Discov. Today"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.drudis.2010.11.014","article-title":"The impact of aromatic ring count on compound developability: Further insights by examining carbo- and hetero-aromatic and -aliphatic ring types","volume":"16","author":"Ritchie","year":"2011","journal-title":"Drug Discov. Today"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"119889","DOI":"10.1016\/j.ijpharm.2020.119889","article-title":"Plasma pharmacokinetics and distribution of ruxolitinib into skin following oral and topical administration in minipigs","volume":"590","author":"Persaud","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"984","DOI":"10.4049\/jimmunol.179.2.984","article-title":"IL-4 and IL-13 negatively regulate TNF-\u03b1- and IFN-\u03b3-induced \u03b2-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3","volume":"179","author":"Albanesi","year":"2007","journal-title":"J. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.4049\/jimmunol.0901860","article-title":"IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation","volume":"184","author":"Sehra","year":"2010","journal-title":"J. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jaci.2006.07.015","article-title":"Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis","volume":"118","author":"Neis","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.anai.2018.02.012","article-title":"JAK\/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease","volume":"120","author":"Howell","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"33676","DOI":"10.1074\/jbc.M204204200","article-title":"Interleukin-22 (IL-22) activates the JAK\/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10","volume":"277","author":"Lejeune","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cytogfr.2008.08.003","article-title":"Structures and biological functions of IL-31 and IL-31 receptors","volume":"19","author":"Zhang","year":"2008","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaci.2020.06.012","article-title":"Atopic dermatitis displays stable and dynamic skin transcriptome signatures","volume":"147","author":"Rodriguez","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"bau007","DOI":"10.1093\/database\/bau007","article-title":"TSLP signaling pathway map: A platform for analysis of TSLP-mediated signaling","volume":"2014","author":"Zhong","year":"2014","journal-title":"Database"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2249.2007.03356.x","article-title":"The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease","volume":"148","author":"Afzali","year":"2007","journal-title":"Clin. Exp. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.clindermatol.2007.08.013","article-title":"Resident skin cells in psoriasis: A special look at the pathogenetic functions of keratinocytes","volume":"25","author":"Albanesi","year":"2007","journal-title":"Clin. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1084\/jem.20030451","article-title":"Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris","volume":"199","author":"Lee","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature05505","article-title":"Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Boutet, M.-A., Nerviani, A., Gallo Afflitto, G., and Pitzalis, C. (2018). Role of the IL-23\/IL-17 axis in psoriasis and psoriatic arthritis: The clinical importance of its divergence in skin and joints. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020530"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"34605","DOI":"10.1074\/jbc.M705100200","article-title":"IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner","volume":"282","author":"Wei","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.2741\/4054","article-title":"IL-6, IL-17 and STAT3: A holy trinity in auto-immunity?","volume":"17","author":"Camporeale","year":"2012","journal-title":"Front. Biosci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1084\/jem.188.6.1203","article-title":"High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo","volume":"188","author":"Ogg","year":"1998","journal-title":"J. Exp. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/jid.2009.32","article-title":"Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients","volume":"129","author":"Konijnenberg","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/pcmr.12667","article-title":"CXCL-10 and interleukin-6 are reliable serum markers for vitiligo activity: A multicenter cross-sectional study","volume":"31","author":"Abdallah","year":"2018","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1038\/jid.2015.335","article-title":"Transcriptional analysis of vitiligo skin reveals the alteration of WNT pathway: A promising target for repigmenting vitiligo patients","volume":"135","author":"Regazzetti","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4132\/jptm.2018.09.18","article-title":"Immunohistochemistry of Janus kinase 1 (JAK1) expression in vitiligo","volume":"52","author":"Abdou","year":"2018","journal-title":"J. Pathol. Transl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00403-017-1792-6","article-title":"Expression of Janus kinase 1 in vitiligo & psoriasis before and after narrow band UVB: A case-control study","volume":"310","author":"Nada","year":"2018","journal-title":"Arch. Dermatol. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/1203475419833609","article-title":"The use of Janus kinase inhibitors in vitiligo: A review of the literature","volume":"23","author":"Relke","year":"2019","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"eaas9673","DOI":"10.1126\/sciimmunol.aas9673","article-title":"Location, location, location: Tissue resident memory T cells in mice and humans","volume":"4","author":"Szabo","year":"2019","journal-title":"Sci. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3389\/fimmu.2019.01018","article-title":"Editorial: Tissue Resident Memory T Cells","volume":"10","author":"Tartour","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"618897","DOI":"10.3389\/fimmu.2020.618897","article-title":"Pathophysiology of Skin Resident Memory T Cells","volume":"11","author":"Tokura","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jid.2017.08.038","article-title":"Vitiligo Skin Is Imprinted with Resident Memory CD8 T Cells Expressing CXCR3","volume":"138","author":"Boniface","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.immuni.2017.01.009","article-title":"CD49a Expression Defines Tissue-Resident CD8+ T Cells Poised for Cytotoxic Function in Human Skin","volume":"46","author":"Cheuk","year":"2017","journal-title":"Immunity"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jid.2018.10.032","article-title":"Resident Memory and Recirculating Memory T Cells Cooperate to Maintain Disease in a Mouse Model of Vitiligo","volume":"139","author":"Richmond","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"6719","DOI":"10.4049\/jimmunol.0904089","article-title":"Distinct roles for IL-2 and IL-15 in the differentiation and survival of CD8+ effector and memory T cells","volume":"184","author":"Mitchell","year":"2010","journal-title":"J. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Fr\u0105czek, A., Owczarczyk-Saczonek, A., and Placek, W. (2020). The Role of TRM Cells in the Pathogenesis of Vitiligo-A Review of the Current State-Of-The-Art. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21103552"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Atwa, M.A., Ali, S.M.M., Youssef, N., and Mahmoud Marie, R.E.S. (2020). Elevated serum level of interleukin-15 in vitiligo patients and its correlation with disease severity but not activity. J. Cosmet. Dermatol.","DOI":"10.1111\/jocd.13908"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1126\/science.7973659","article-title":"Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits","volume":"266","author":"Miyazaki","year":"1994","journal-title":"Science"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","article-title":"Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1056\/NEJMra1103442","article-title":"Alopecia areata","volume":"366","author":"Gilhar","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1586\/1744666X.2015.1085306","article-title":"The role of lymphocytes in the development and treatment of alopecia areata","volume":"11","author":"Guo","year":"2015","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/exd.12209","article-title":"What causes alopecia areata?","volume":"22","author":"McElwee","year":"2013","journal-title":"Exp. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/exd.12918","article-title":"Biomarkers of alopecia areata disease activity and response to corticosteroid treatment","volume":"25","author":"Gulati","year":"2016","journal-title":"Exp. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nri3919","article-title":"IL-15 functions as a danger signal to regulate tissue-resident T cells and tissue destruction","volume":"15","author":"Jabri","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"15722","DOI":"10.1038\/srep15722","article-title":"Trans-presentation of IL-15 modulates STAT5 activation and Bcl-6 expression in TH1 cells","volume":"5","author":"Cooley","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jaad.2011.12.018","article-title":"Preliminary clinical activity of a topical JAK1\/2 inhibitor in the treatment of psoriasis","volume":"67","author":"Punwani","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jaad.2019.10.016","article-title":"Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study","volume":"82","author":"Olsen","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.jaad.2020.02.009","article-title":"Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study","volume":"82","author":"Kim","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: A randomised, controlled, phase 2 trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/7\/1044\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:27:56Z","timestamp":1760164076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/7\/1044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":79,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["pharmaceutics13071044"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics13071044","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,8]]}}}